vaginal infections and preterm birth - an update
DESCRIPTION
Vaginal Infections and Preterm Birth - An Update. J. Chris Carey, MD. Disponible en: http://www.ihs.gov/MedicalPrograms/MCH/M/documents/VIPPRES2.PPT. History Rationale Asymptomatic bacteriuria Gonorrhea Syphilis Genital Mycoplasmas. Chlamydia trachomatis Group B strep - PowerPoint PPT PresentationTRANSCRIPT
Vaginal Infections and Vaginal Infections and Preterm Birth -Preterm Birth -
An UpdateAn Update
J. Chris Carey, MDJ. Chris Carey, MD
Disponible en: Disponible en: http://www.ihs.gov/MedicalPrograms/MCH/M/documents/VIPPRES2.PPThttp://www.ihs.gov/MedicalPrograms/MCH/M/documents/VIPPRES2.PPT
•OverviewOverview• HistoryHistory• RationaleRationale• Asymptomatic Asymptomatic
bacteriuriabacteriuria• GonorrheaGonorrhea• SyphilisSyphilis• Genital Genital
MycoplasmasMycoplasmas
• Chlamydia Chlamydia trachomatistrachomatis
• Group B strepGroup B strep• Periodontal Periodontal
diseasedisease• Bacterial vaginosisBacterial vaginosis• Trichomonas Trichomonas
vaginalisvaginalis
RationaleRationale• Preterm birth is the leading cause Preterm birth is the leading cause
of neonatal morbidity and of neonatal morbidity and mortalitymortality
• Increasing body of evidence to Increasing body of evidence to indicate that infections are indicate that infections are associated with preterm birthassociated with preterm birth
Evidence linking Evidence linking infection with preterm infection with preterm
birthbirth• Histologic Chorioamnionitis is more Histologic Chorioamnionitis is more
common in preterm deliveriescommon in preterm deliveries• Postpartum endomyometritis (PPE) Postpartum endomyometritis (PPE)
is more common after preterm is more common after preterm deliveries deliveries
• Preterm delivery is more common Preterm delivery is more common in women with a variety of genital in women with a variety of genital infectionsinfections
% PPE by Gestational % PPE by Gestational AgeAge
VIP studyVIP studyVaginal Deliveries
05
10
1520
30 31 32 33 34 35 36 37 38 39 40 41 42 >42
Weeks
% P
PE
Risk factors for PPERisk factors for PPEFactorFactor Adjusted ORAdjusted OR 95% CI95% CI2 sex 2 sex partnerspartners
2.12.1 1.2-3.71.2-3.7
> 2 partners> 2 partners 1.61.6 0.7-3.90.7-3.9Pregnancy Pregnancy UTIUTI
1.81.8 1.0-3.41.0-3.4
Pressure Pressure cathcath
2.02.0 1.2-3.41.2-3.4
ROM > 12 hROM > 12 h 2.22.2 1.2-4.31.2-4.3
Gest Gest < < 34 w34 w 6.26.2 2.9-13.42.9-13.4
Mechanism for preterm Mechanism for preterm laborlabor
C ontractions
M ultip le organ system s
Fetal u rine Placental - cerv icalvaginal in fection
A ctivated decidual m acrophages
D ecidua
I ntra am n iotic prostagland in
C el l to cel l gap junctions
C a++ release
A ctin -m yosin
Shortened m yom etrial fi bers
PgE , m C SF, I L 1, T N F
Fibrob lasts, W B C s
I ncreased col lagenases
D ecreased col lagen
A ctive ripen ing
C erv ical eff acem ent
Asymptomatic Asymptomatic bacteriuriabacteriuria
• Occurs in 3 - 10 % of pregnant Occurs in 3 - 10 % of pregnant womenwomen
• First asymptomatic infection to be First asymptomatic infection to be linked to preterm birthlinked to preterm birth
Asymptomatic Asymptomatic bacteriuriabacteriuria
• Kass (NY State J Med 1962:62: Kass (NY State J Med 1962:62: 2815) showed2815) showed
• 24% preterm birth in untreated24% preterm birth in untreated• 10% in treated10% in treated• 10% in controls10% in controls
Asymptomatic Asymptomatic bacteriuriabacteriuria
Elder, AJOG 1971:111;441Elder, AJOG 1971:111;441TetracyclineTetracycline PlaceboPlacebo
Birthwt (oz)Birthwt (oz) 115.6115.6 110.8110.8TermTerm 137137 110110 % term% term 93.293.2 83.383.3PretermPreterm 88 2020 % preterm% preterm 5.45.4 15.215.2IUFDIUFD 22 11 % IUFD% IUFD 1.41.4 0.80.8AbortionAbortion 00 11
Asymptomatic Asymptomatic bacteriuriabacteriuria
• Screen all women at first visitScreen all women at first visit• Treatment reduces risk of Treatment reduces risk of
pyelonephritispyelonephritis
SyphilisSyphilis• Effects of untreated syphilis Effects of untreated syphilis
include stillbirth, preterm birth and include stillbirth, preterm birth and congenital anomaliescongenital anomalies
• Half of congenital syphilis occurs in Half of congenital syphilis occurs in women with no prenatal carewomen with no prenatal care
• Screen all pregnant women at first Screen all pregnant women at first visit – high risk in third trimestervisit – high risk in third trimester
GonorrheaGonorrhea• Occurs in 1 - 6 % of pregnant Occurs in 1 - 6 % of pregnant
womenwomen• Untreated gonorrhea associated Untreated gonorrhea associated
with preterm delivery and PPROMwith preterm delivery and PPROM• Treatment of gonorrhea reduces Treatment of gonorrhea reduces
risk risk
Genital MycoplasmasGenital Mycoplasmas• Ureaplasma urealyticumUreaplasma urealyticum
• Found in 50 - 90% of pregnant womenFound in 50 - 90% of pregnant women• Early studies indicated strong Early studies indicated strong
association with preterm birthassociation with preterm birth• Later studies fail to confirm Later studies fail to confirm
associationassociation
Ureaplasma treatment Ureaplasma treatment trial - VIPtrial - VIP
• 1181 women - 605 erythromycin, 1181 women - 605 erythromycin, 576 placebo576 placebo
• No difference in No difference in • mean birth weight mean birth weight • low birth weightlow birth weight• delivery < 37 weeksdelivery < 37 weeks• delivery < 32 weeksdelivery < 32 weeks
Genital MycoplasmasGenital Mycoplasmas• Mycoplasma hominisMycoplasma hominis
• Inconclusive results from studiesInconclusive results from studies• ¿ Association with BV ?¿ Association with BV ?
Chlamydia trachomatisChlamydia trachomatis• Early studies showed a strong Early studies showed a strong
association with preterm delivery association with preterm delivery and neonatal deathand neonatal death
• Later studies show an association Later studies show an association with preterm delivery and low birth with preterm delivery and low birth weightweight
• Treatment trials are inconclusiveTreatment trials are inconclusive
Chlamydia treatment Chlamydia treatment trial - VIPtrial - VIP
< 2500gm
PPROM PTL < 37 PTD < 37
Erythro 16/183(8.7%)
5/181(2.8%)
22/181(12.2%)
25/183(13.7%)
Placebo 22/183(12%)
7/179(3.9%)
23/179(12.9%)
29/184(15.8%)
Group B strepGroup B strep• Early studies showed association Early studies showed association
between early onset GBS sepsis and between early onset GBS sepsis and preterm birthpreterm birth
• Early studies also showed association Early studies also showed association between preterm birth and GBS between preterm birth and GBS carriagecarriage
• Large study showed weak associationLarge study showed weak association• Treatment trials showed no effect of Treatment trials showed no effect of
therapytherapy
Group B StrepGroup B Strep• VIP study resultsVIP study results
• GBS recovered from 21 % of 13,646 womenGBS recovered from 21 % of 13,646 women• Heavy colonization was associated with a Heavy colonization was associated with a
modest risk of preterm low birth weight modest risk of preterm low birth weight infant (RR 1.5, 95% CI 1.1-1.9 )infant (RR 1.5, 95% CI 1.1-1.9 )
• Light colonization showed no increase riskLight colonization showed no increase risk• Treatment with antibiotics active against Treatment with antibiotics active against
GBS reduced risk in heavily colonized GBS reduced risk in heavily colonized womenwomen
• Regan et al AJOG 1996;174:1354-60Regan et al AJOG 1996;174:1354-60
Group B Strep Group B Strep treatment trial - VIP treatment trial - VIP
Outcome Erythro-mycin
Placebo RR C.I
<2500 gm
8.6 % 6.1 % 1.4 0.9-2.2
< 37 wks 11.4% 12.3% 0.9 0.6-1.3
Group B StrepGroup B Strep• VIP studyVIP study
• Randomized clinical trial of Randomized clinical trial of erythromycin did not reduce the risk erythromycin did not reduce the risk of preterm birth in women colonized of preterm birth in women colonized with GBSwith GBS
Bacterial vaginosisBacterial vaginosis• Occurs in 20 – 30 % of Occurs in 20 – 30 % of
asymptomatic womenasymptomatic women• Approximately 1,000,000 cases/yr Approximately 1,000,000 cases/yr
in USA in pregnant womenin USA in pregnant women• Numerous studies show Numerous studies show
association with preterm birthassociation with preterm birth
Bacterial vaginosisBacterial vaginosis• Gravett, 1986 JAMAGravett, 1986 JAMA• N=534 pregnant women (102 with N=534 pregnant women (102 with
BV)BV)• BV associated withBV associated with
• PROM (RR= 2.4)PROM (RR= 2.4)• Preterm labor (RR = 2.0)Preterm labor (RR = 2.0)• IAI (RR = 2.7)IAI (RR = 2.7)
Bacterial vaginosisBacterial vaginosis• Kurki - Obstet Gynecol 1992Kurki - Obstet Gynecol 1992• N = 790 pregnant womenN = 790 pregnant women
• BV by culture 21.4%BV by culture 21.4%• BV by Gram stain 21.1%BV by Gram stain 21.1%
• BV associated withBV associated with• PTL RR 2.6PTL RR 2.6• PTB RR 6.9PTB RR 6.9• PPROM RR 7.3PPROM RR 7.3
Bacterial VaginosisBacterial Vaginosis• Hay – BMJ 1994Hay – BMJ 1994• N=783, screened at 9-24 weeksN=783, screened at 9-24 weeks• BV associated with BV associated with
• PTD – RR 2.8PTD – RR 2.8• Late miscarriage – 5.5Late miscarriage – 5.5
Bacterial vaginosisBacterial vaginosis• Total of 11 studies show increase Total of 11 studies show increase
in PTB with RR ranging from 2 - 4in PTB with RR ranging from 2 - 4
Bacterial vaginosisBacterial vaginosis• VIP data – Hillier NEJM 1995VIP data – Hillier NEJM 1995• N = 10,397 women without N = 10,397 women without
chlamydia, TV or GBSchlamydia, TV or GBS• BV in 1645BV in 1645
• PTD – rr 1.4PTD – rr 1.4• LBW – rr 1.5 LBW – rr 1.5
BV treatment trialsBV treatment trials• Clindamycin trialsClindamycin trials
• McGregor AJOG 1994McGregor AJOG 1994• Joesoef AJOG 1995Joesoef AJOG 1995
• Metronidazole trialsMetronidazole trials• Morales AJOG 1994Morales AJOG 1994• McDonald et al - Br J Obstet Gyn McDonald et al - Br J Obstet Gyn
1997;104:13911997;104:1391
BV treatment trial BV treatment trial Morales AJOG 1994Morales AJOG 1994
01020304050607080
PTB PROM PTL LBW
MetroPlacebo
Treatment of BVTreatment of BVHauth NEJM 1995Hauth NEJM 1995
• 263 high-risk women with BV263 high-risk women with BV• Randomized 2:1 metro + erythro Randomized 2:1 metro + erythro
or placeboor placebo• Incidence of PTDIncidence of PTD
• < 37 w - 37% v 23%< 37 w - 37% v 23%• < 34 w - 19% v 11%< 34 w - 19% v 11%• < 32 w - 11% v 6%< 32 w - 11% v 6%
Treatment of BVTreatment of BVMcGregor AJOG 1994McGregor AJOG 1994
0
5
10
15
20
25
PTB PROM PTL LBW
Clindamycin CreamPlacebo
Treatment of BVTreatment of BVJoeseof, AJOG 1995Joeseof, AJOG 1995
02468
10121416
PTB < 37 PTB < 32 LBW
CVCPlacebo
Other clindamycin trialsOther clindamycin trialsAuthorAuthor NN RouteRoute ClindaClinda PlacebPlaceb
ooKurkinen-Kurkinen-RatyRaty 101101 VaginalVaginal 13.7%13.7% 6.0%6.0%KekkiKekki 375375 VaginalVaginal 5%5% 4%4%UgwumaduUgwumadu 494494 OralOral 5.3%5.3% 15.8%15.8%VermuelenVermuelen 168168 VaginalVaginal 23%23% 18%18%LamontLamont 409409 VaginalVaginal 4%4% 10%10%
McDonald BV trialMcDonald BV trial• 879 women with BV by Gram stain 879 women with BV by Gram stain
or culture for G Vaginalis at 19 or culture for G Vaginalis at 19 weeksweeks
• Oral metronidazole 400 mg BID for Oral metronidazole 400 mg BID for 2 days or placebo at 24 weeks and 2 days or placebo at 24 weeks and at 29 weeks if persistent at 29 weeks if persistent
McDonald BV trialMcDonald BV trialOutcome Metronidazole Placebo
Overalldelivery < 37
31/429 (7.2%) 32/428 (7.5%)
Spontaneousdelivery < 37
20/429 (4.7%) 24/428 (5.6%)
Mc Donald BV trialMc Donald BV trialSpontaneousPTD
Metronidazole Placebo
BV by gramn=480
11/242 (4.5%) 15/238 (6.3%)
Prior PTDn=46
2/22 (9.1%) 10/24 (41.7%)
Compliantwith priorPTD and BV
0/14 (0%) 6/17 (35.3%)
MFMU BV StudyMFMU BV StudyNEJM 2000NEJM 2000
• Purpose – To determine whether Purpose – To determine whether treatment of BV with metronidazole treatment of BV with metronidazole would prevent preterm birthwould prevent preterm birth
• Screened from 8-22 weeksScreened from 8-22 weeks• Treated with 2 grams metro on day Treated with 2 grams metro on day
1 and 3 from 13 – 24 weeks1 and 3 from 13 – 24 weeks• Treatment repeated late second Treatment repeated late second
trimestertrimester
MFMU BV study MFMU BV study MetroMetro PlacebPlaceb
ooRRRR 95% CI95% CI
nn 953953 966966< 37 w< 37 w 12.2%12.2% 12.5%12.5% 0.970.97 0.8-1.20.8-1.2PTLPTL 5.15.1 5.75.7 0.90.9 0.6-1.30.6-1.3PPROMPPROM 4.24.2 3.73.7 1.121.12 0.7-1.80.7-1.8LBWLBW 10.910.9 11.411.4 0.960.96 0.5-1.50.5-1.5
MFMU Trichomonas MFMU Trichomonas trialtrial
• Carriage of Carriage of T. vaginalisT. vaginalis increases increases risk of preterm birthrisk of preterm birth
• T. vaginalisT. vaginalis commonly found with commonly found with BVBV
• T. vaginalisT. vaginalis is common and often is common and often asymptomaticasymptomatic
PurposePurpose• To determine if To determine if
metronidazole treatment metronidazole treatment would prevent preterm would prevent preterm birth in asymptomatic birth in asymptomatic women who carried women who carried T. T. vaginalisvaginalis
ResultsResultsConsidered forculture
40,857
Ineligible 7,768Refused screen 1,711Test not done 221Cultures done 31,157TV positive 2,377
7.6%
ResultsResultsTV positive 2,377
Ineligible for trial 1,333
Refused consent 265
No show for visit 152
Randomized in error to BV trial 12
Randomized* *includes two TV negative patients
617
RandomizedRandomized• 297 patients randomized to 297 patients randomized to
placeboplacebo• 320 randomized to metronidazole320 randomized to metronidazole
• The study was stopped early by The study was stopped early by the Data Safety Monitoring Boardthe Data Safety Monitoring Board
Effectiveness of Effectiveness of therapytherapy
Persistence of TV At 24-29 weeks
Metronidazole 20/277 (7%)
Placebo 168/267 (63%)
ResultsResults
Metro Placebo RR 95%CI
Total PTD 19.0% 10.7% 1.78 1.19-2.66PTD-PTL 10.3% 3.5% 2.95 1.48-5.90PTD-PPROM 4.5% 4.2% 1.08 0.51-2.29<32 weeks 5.1% 3.8% 1.33 0.63-2.83< 2500 gm 16.4% 11.8% 1.38 0.92-2.07< 1500 gm 5.5% 3.8% 1.43 0.68-2.99
ResultsResults
Metro Placebo CI
PTD – BVpositive
26.1% 14.2% 1.84(1.07-3.18)
PTD – BVnegative
14.9% 8.7% 1.72(0.96-3.11)
IAI 7.8% 8.4% NS
PPE 4.2% 4.2% NS
What can we learn from What can we learn from the treatment trials of the treatment trials of
BV?BV?• Treatment of women with a prior Treatment of women with a prior
PTD with metronidazole and PTD with metronidazole and erythromycin may reduce the risk erythromycin may reduce the risk of subsequent PTD but does not of subsequent PTD but does not reduce the risk in women who do reduce the risk in women who do not have BVnot have BV
• Women with a prior PTD may be in Women with a prior PTD may be in some way different some way different
What should we do in What should we do in clinical practice?clinical practice?
• Screen and treat for gonorrhea, Screen and treat for gonorrhea, syphilis, asymptomatic bacteriuria, syphilis, asymptomatic bacteriuria, chlamydiachlamydia
• Screen women with a prior PTD for Screen women with a prior PTD for BV and treat with metronidazole and BV and treat with metronidazole and erythromycin?erythromycin?
• DO NOT treat BV with clindamycin DO NOT treat BV with clindamycin vaginal creamvaginal cream
• DO NOT treat asymptomatic trichDO NOT treat asymptomatic trich
ConclusionsConclusions• The more we learn, the less we know The more we learn, the less we know
about infections and preterm deliveryabout infections and preterm delivery• Antibiotic therapy in pregnancy may Antibiotic therapy in pregnancy may
be harmfulbe harmful• Treatment of infections in pregnancy Treatment of infections in pregnancy
should only be done if clear benefit should only be done if clear benefit has been shown from randomized has been shown from randomized trialstrials